160 related articles for article (PubMed ID: 33871044)
1. The effect of buprenorphine vs methadone on sleep breathing disorders.
Adimi Naghan P; Setareh J; Malekmohammad M
Adv Respir Med; 2021; 89(4):439-443. PubMed ID: 33871044
[TBL] [Abstract][Full Text] [Related]
2. Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series.
DeVido J; Connery H; Hill KP
J Opioid Manag; 2015; 11(4):363-6. PubMed ID: 26312963
[TBL] [Abstract][Full Text] [Related]
3. Case of buprenorphine-associated central sleep apnea resolving with dose reduction.
Tchikrizov V; Richert AC; Bhardwaj SB
J Opioid Manag; 2022; 18(4):391-394. PubMed ID: 36052936
[TBL] [Abstract][Full Text] [Related]
4. A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients.
Hassamal S; Miotto K; Wang T; Saxon AJ
Am J Addict; 2016 Sep; 25(6):452-65. PubMed ID: 27554389
[TBL] [Abstract][Full Text] [Related]
5. Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.
Dunn KE; Finan PH; Andrew Tompkins D; Strain EC
Addict Behav; 2018 Jan; 76():8-14. PubMed ID: 28735039
[TBL] [Abstract][Full Text] [Related]
6. Multimodal assessment of sleep in men and women during treatment for opioid use disorder.
Finan PH; Mun CJ; Epstein DH; Kowalczyk WJ; Phillips KA; Agage D; Smith MT; Preston KL
Drug Alcohol Depend; 2020 Feb; 207():107698. PubMed ID: 31816489
[TBL] [Abstract][Full Text] [Related]
7. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Bishop B; Gilmour J; Deering D
Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
[TBL] [Abstract][Full Text] [Related]
8. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
9. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
Soyka M; Groß G
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
[TBL] [Abstract][Full Text] [Related]
10. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
Holbrook AM
Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531
[TBL] [Abstract][Full Text] [Related]
11. Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys.
Berro LF; Zamarripa CA; Talley JT; Freeman KB; Rowlett JK
Addict Behav; 2022 Dec; 135():107433. PubMed ID: 35901553
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment.
Maremmani I; Gerra G
Am J Addict; 2010; 19(6):557-68. PubMed ID: 20958853
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
14. Use and misuse of opioid agonists in opioid addiction.
Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
[TBL] [Abstract][Full Text] [Related]
15. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
16. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
[TBL] [Abstract][Full Text] [Related]
17. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
Guan Q; Khuu W; Spithoff S; Kiran T; Kahan M; Tadrous M; Martins D; Leece P; Gomes T
Drug Alcohol Depend; 2017 Aug; 177():315-321. PubMed ID: 28733101
[TBL] [Abstract][Full Text] [Related]
18. Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone.
Farney RJ; McDonald AM; Boyle KM; Snow GL; Nuttall RT; Coudreaut MF; Wander TJ; Walker JM
Eur Respir J; 2013 Aug; 42(2):394-403. PubMed ID: 23100497
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison.
Unger A; Jagsch R; Jones H; Arria A; Leitich H; Rohrmeister K; Aschauer C; Winklbaur B; Bäwert A; Fischer G
Addiction; 2011 Jul; 106(7):1355-62. PubMed ID: 21438938
[TBL] [Abstract][Full Text] [Related]
20. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
